Exploring the Anxiolytic Potential of NPY by a Dipeptidyl Peptidase-IV Inhibitor in an Animal Model of PTSD Authors: Matan Dahan, Joseph Zohar, Doron Todder, Aleksander A Mathé, Hagit Cohen Published: 2024 ABSTRACT AbstractBackgroundThe regulatory neuropeptide Y (NPY) is implicated in anxiety and post-traumatic stress disorder (PTSD)-related behaviors. NPY exerts its effects through 5 receptor subtypes, with Y1 and Y2 receptors being predominantly expressed in the rat brain. Activation of Y1 by full-length NPY1-36 induces anxiolytic effects, whereas Y2 binds truncated peptides, eliciting region-specific anxiogenic responses. Dipeptidyl peptidase-IV (DPP-IV) cleaves NPY, thereby modulating its functionality. Sitagliptin, a DPP-IV inhibitor (DPP-IV-I), inhibits the degradation of various vasoactive peptides, including cerebral NPY. As such, the therapeutic potential of DPP-IV-I following a traumatic event remains inconclusive. We assessed the effects of a highly selective DPP-IV-I, administered either shortly after the stressor or intermittently over 3 days, on behavioral outcomes using the predator scent stress (PSS) model of PTSD.MethodsRats exposed to PSS or sham-PSS received a single dose of sitagliptin (10 or 30 mg/kg) or saline 1 hour post-exposure, or repeated doses over 3 days (20 mg/kg). Behavioral outcomes were evaluated using the elevated plus maze and acoustic startle response at 7 days post-exposure. Additionally, rats exposed to PSS or sham-PSS were treated with sitagliptin (30 mg/kg) or saline, and their brains were prepared for immunofluorescence and enzyme-linked immunosorbent assay (ELISA).ResultsSitagliptin did not attenuate anxiety-related behaviors or PTSD-related behavior prevalence compared to saline. Notably, the 30 mg/kg dose increased NPY levels in several brain regions without affecting NPY-Y1 levels.ConclusionsThe findings suggest that sitagliptin-induced upregulation of NPY levels shortly after PSS is insufficient to prevent the development of post-traumatic responses. The effectiveness of NPY signaling may be influenced by factors beyond peptide concentration alone, potentially limiting its therapeutic efficacy. Activation of NPY-Y1 receptors, rather than merely increasing NPY levels, appears to be crucial for modulating anti-anxiety and post-traumatic responses. Significance Statement The intricate interplay between neuropeptide Y (NPY) and its receptors reveals a complex landscape in the domain of anxiety and post-traumatic stress disorder (PTSD). The study explores the therapeutic potential of sitagliptin, a DPP-IV inhibitor, in mitigating anxiety and PTSD-related behaviors through the modulation of neuropeptide Y pathways. Despite sitagliptin’s ability to elevate NPY levels, it failed to alleviate anxiety or PTSD-like behaviors in rats exposed to predator scent stress (PSS). Intriguingly, higher sitagliptin doses increased NPY levels in various brain regions without affecting NPY-Y1 expression. This suggests that the effectiveness of NPY signaling is modulated by factors beyond the peptide’s concentration, underscoring the importance of selective activation of NPY-Y1 receptors in modulating anti-anxiety and post-traumatic responses. Consequently, the study highlights the complexity of NPY’s role in stress-related disorders and emphasizes the need for targeted therapeutic approaches that focus on specific receptor pathways, rather than merely increasing NPY levels. INTRODUCTION Neuropeptide Y (NPY) is a highly conserved 36-amino acid residue long peptide named after its C-terminally amidated tyrosine, which is widely distributed throughout the peripheral and central nervous system (Adrian et al., 1983; de Quidt and Emson, 1986). NPY originates from a precursor molecule known as pre-pro-NPY, which comprises 97 amino acids. The conversion of pre-pro-NPY into its final peptide form involves enzymatic processes mediated by prohormone-converting enzymes and a carboxypeptidase-like enzyme. Furthermore, the peptide undergoes amidation to yield the biologically active form of NPY, specifically NPY1-36 (Brakch et al., 1997). In the brain, NPY is primarily expressed in and released from GABAergic interneurons in response to sustained neuronal activity (Vezzani et al., 1999). However, it is also found in astrocytes (Ramamoorthy and Whim, 2008) and certain projection neurons (Wahlestedt et al., 1989). Additionally, it may enter the brain from the bloodstream through diffusion across the blood–brain barrier (BBB) (Gøtzsche and Woldbye, 2016). The biological actions of NPY are mediated by the activation of at least 5 types of molecularly defined G-coupled receptors family designated Y1 through Y6 receptor subtypes (Kask et al., 2002). The Y1 receptor has a high affinity for full-length NPY1-36, mediating its anxiolytic effects, while Y2 and Y5 receptors bind C-terminal truncated peptide forms that trigger anxiogenic effects (Fuhlendorff et al., 1990; King et al., 2000), although these responses appear to be region-specific (Kask et al., 2002). These 3 NPY receptors, Y1, Y2, and relatively Y5 represent the major subtypes expressed in the rat brain (Kask et al., 2002). NPY is a prototypical peptide whose function can be altered by proteases (Kask et al., 2002). Ectoenzymes, such as dipeptidyl peptidase-IV (DPP-IV) (which functions as a cell surface serine protease, selectively cleaving dipeptides from peptides and proteins containing proline or alanine in the N-terminal penultimate position (Frerker et al., 2007; Wagner et al., 2016), cleave NPY by removing the first 2 N-terminal amino acid residues (Tyr-Pro), resulting in the generation of C-terminal fragments 3-36 (Kask et al., 2002). NPY3-36 exhibits significantly reduced affinity to the NPY-Y1 receptor subtype but retains potency equivalent to the native peptide on the NPY-Y2 and Y5 receptor subtypes (Kask et al., 2002). Therefore, DPP-IV may shift the actions of NPY from Y1 receptor-mediated anxiolytic effects to Y2 receptor-mediated anxiogenic effects. In fact, besides NPY, there are more than 30 known peptide substrates for DPP-IV such as hormonal peptides belonging to the glucagon superfamily—glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP). Thus, DPP-IV inhibitors, such as gliptins including sitagliptin, are widely used to enhance the incretin effect of GLP-1 and GIP, thereby improving postprandial glycemic control in patients with type 2 diabetes (Frerker et al., 2007; Wagner et al., 2016). NPY has a role in the regulation of various physiological functions, such as food intake (Clark et al., 1985; Kalra et al., 1999; Beck, 2000), metabolic functions (Small et al., 1997; Krysiak et al., 1999), circadian rhythm (White, 1993), cognition (Redrobe et al., 1999), neuronal excitability (Colmers and Bleakman, 1994), and addictions and modulation of emotional responses to various stressors (Heilig and Widerlöv, 1995; Heilig, 2004; Mathé et al., 2007; Cohen et al., 2012; Sabban et al., 2016). Consistent findings from various rodent models of anxiety provide evidence supporting the notion that NPY exhibits an anxiolytic effect (Wu et al., 2011; Cohen et al., 2012; Sabban et al., 2016). This effect, at least in rats, is comparable in potency to benzodiazepines and can be observed following a single dose (Cohen et al., 2012). Recently, we reported a significant decrease in NPY levels within specific brain regions in animals displaying behavioral changes after predator scent stress (PSS) in an animal model of PTSD (Cohen et al., 2012). We found a pronounced association between the extent of behavioral disturbances and the NPY level patterns. Animals exhibiting highly disrupted behavior (PTSD-phenotype) showed substantial downregulation of NPY specifically in the periaqueductal gray (PAG), hippocampus, and amygdala compared to unexposed controls. Furthermore, manipulating NPY levels significantly influenced both behavioral and neurobiological responses to the PSS paradigm (Cohen et al., 2012). Blocking the NPY-Y1 receptor during PSS resulted in extreme effects, underscoring the critical protective role of endogenous NPY, while centrally administered NPY raised endogenous NPY levels and alleviated the behavioral effects of PSS. Consequently, enhancing (endogenous or exogenous) NPY expression shortly after trauma in susceptible individuals holds the potential for promoting resilience and reducing the risk of developing PTSD. Due to the pleiotropic effects of DPP-IV, mutant F344 rats deficient in DPP-IV exhibit reduced stress responses across various paradigms, including the open field, social interaction, and passive avoidance tests (Karl et al., 2003a, b). This reduced stress response observed in DPP-IV-deficient rats is also noticeable in NPY-overexpressing transgenic rats (Thorsell et al., 2000; Canneva et al., 2015), providing additional evidence that supports the involvement of NPY in the decreased anxiety observed in the mutant F344 strains (Karl et al., 2003a, b). DPP-IV inhibitors, such as sitagliptin (6 mg/kg), may have mild antinociceptive, antidepressant, and cognitive benefits in animal models of depression (Kamble et al., 2016). Sitagliptin (20 mg/kg, p.o.) exhibits an anxiolytic effect in the elevated plus maze (EPM) test in rats (Sharma et al., 2015). It also potentiates the anxiolytic effect of ethanol when rats are treated with sub-effective doses of ethanol (1.5 g/kg, i.p.) and sitagliptin (5 mg/kg, p.o.) in the EPM behavior test (Sharma et al., 2015). However, the therapeutic efficacy of a DPP-IV inhibitor following a traumatic experience remains uncertain. This study aimed to investigate whether early treatment with sitagliptin, a highly selective DPP-IV inhibitor, administered shortly after stress exposure (as secondary prevention), can increase endogenous levels of central NPY and the route of its action toward Y1 receptor-mediated anxiolytic effects. This, in turn, could potentially reduce the risk of developing PTSD and promote resilience. METHODS All treatment and testing procedures were approved by the Animal Care Committee of Ben-Gurion University of the Negev, Israel. Animals Male Sprague–Dawley rats weighing 200-250 grams were acclimatized to housing conditions for a minimum of 7 days. The animals were group-housed (2-3 per cage) at the Veterinary Unit of the Beer-Sheva Mental Health Center. They were maintained on a 12-hour light-dark cycle (lights off at 07:00 AM) with controlled temperature (22 ± 1 °C) and relative humidity (50%-70%) and given ad libitum access to food and water. Rats were gently handled once daily with a gloved hand. All testing procedures were conducted during the animals’ active phase under dim light conditions. Experimental Design We conducted 2 experiments to evaluate the effects of acute administration of the DPP-IV inhibitor (sitagliptin) given shortly after the stressor on behavioral stress response parameters in the PSS model of PTSD. In experiment 1 (N = 53), rats were exposed to either PSS (N = 41) or sham-PSS (N = 12) for 30 minutes. One hour later, sitagliptin was administered intraperitoneally (i.p.) at doses of 10 mg/kg (N = 10) or 30 mg/kg (N = 10). A separate group of rats received saline (N = 12) 1 hour after PSS exposure as a control. Additionally, another group of rats received sitagliptin at a dose of 20 mg/kg (N = 9), starting 1 hour after PSS exposure and continuing for 3 consecutive days. Seven days later, the rats underwent behavioral assessments in the EPM and acoustic startle response (ASR) tests. The data obtained were subsequently used for retrospective classification into behavioral response groups, assessing prevalence rates of extreme, partial, and minimal behavioral responses (MBRs). Experiment 2 (N = 19) was designed to elucidate changes in NPY levels associated with PSS and sitagliptin treatment, utilizing both immunofluorescence staining (N = 9) and ELISA (N = 10) techniques. Rats were exposed to either PSS or sham-PSS for 30 minutes. One hour later, sitagliptin (30 mg/kg, N = 7) or saline (N = 6) was administered intraperitoneally. A separate group of rats served as unexposed controls for each technique (N = 6). Two hours after treatment, the rats were anesthetized and perfused. Their brains were rapidly removed, prepared for immunofluorescence staining and ELISA, and stored at −80 °C until analysis. Immunofluorescence staining was used to evaluate the levels of NPY and NPY-Y1 in the paraventricular nucleus of the hypothalamus (PVN), paraventricular nucleus of the thalamus (PVTN), hippocampal CA1 subregion, and amygdala. ELISA was employed to assess NPY levels in the PVN, amygdala, and hippocampus. Predator Scent Stress Rats were individually placed on well-soiled cat litter used for 2 days by a cat and sifted for stools. Rats were exposed to the litter for 30 minutes in a plastic cage (inescapable exposure) placed on a yard’s paving stone in a closed environment. Sham-PSS was administered under similar conditions, but rats were exposed to fresh, unused cat litter. Sitagliptin Administration Sitagliptin (Januvia®, Merck Pharmaceuticals) was purchased from the Beer-Sheva Mental Health Center pharmacy and dissolved in 0.9% saline to concentrations of 10, 20, and 30 mg/kg for intraperitoneal injection. Vehicle groups in each experiment received an equal volume of 0.9% saline solution under the same conditions. Both control and treated animals were weighed weekly to monitor potential body weight changes following treatment. Behavioral Measurements The EMP: The maze consists of a plus-shaped platform with 2 open arms and 2 closed arms—surrounded by 50-cm high opaque walls on 3 sides, with arms of the same type located opposite each other as described by File (1993). Rats were placed on the central platform facing an open arm and allowed to explore the maze for 5 minutes. Each test was videotaped and scored by an independent observer. An arm entry was defined as entering the arm with all 4 paws. The following parameters were measured: duration in open and closed arms, open and closed arm entries, and total entries into all arms. “Anxiety Index,” an index that integrates the EPM behavioral measures, was calculated as follows: Anxiety index values range from 0 to 1, where an increase in the index expresses increased anxiety-like behavior (Cohen et al., 2008). Acoustic startle response: Startle response was measured using 2 ventilated startle chambers (San Diego Instruments, California). Each chamber consists of a Plexiglas cylinder resting on a platform inside a sound-attenuated, ventilated chamber. Movement inside the tube is detected by a piezoelectric accelerometer below the frame. Sound levels within each test chamber are measured routinely using a sound level meter to ensure consistent presentation. Chambers are calibrated daily. The animals were placed inside the tube, and the startle session started with a 5-minute acclimatization period. Following a 5-minute acclimatization period, 30 acoustic startle trials (110 dB white noise; 40 ms duration; 30 or 45 seconds inter-trial interval) were presented over a 68 dB white noise background. Two measures of behavior were assessed: (1) mean startle amplitude; (2) percent of startle response habituation over repeated presentation of the acoustic pulse. Startle amplitudes were averaged over all 30 trials (Cohen et al., 2013). Cutoff behavioral criteria model: Individual rats were classified according to the degrees to which individual behavior was affected by a stressor. The classification of individual rats was based on the premise that extremely compromised behavior in response to the priming trigger is not conducive to survival, inadequate, and maladaptive, and thus represents a pathological degree of responses (Cohen et al., 2003, 2005; Cohen and Zohar, 2004). Please see Supplementary Information 1 for a detailed explanation of the criteria. Immunofluorescence Tissue preparation: Two hours after sitagliptin/vehicle administration, animals were deeply anesthetized (ketamine and xylazine mixture) and perfused transcardially with cold 0.9% physiological saline followed by 4% paraformaldehyde (Sigma-Aldrich, Rehovot, Israel) in 0.1 M phosphate buffer (pH 7.4). Brains were quickly removed, postfixed in the same fixative for 12h at 4 °C, and cryoprotected overnight in 30% sucrose in 0.1 M phosphate buffer at 4 °C. Brains were frozen on dry ice and stored at −80 °C. Serial coronal sections (10 µm) at the level of dorsal hippocampus and amygdala (bregma: −2.80 mm), PVN, and PVTN (bregma: −1.8 mm) corresponding to the rat brain atlas of Paxinos and Wats (Paxinos and Watson, 2013) were collected from each animal using a cryostat (Leica CM 1850, Germany). Sliced sections were air-dried and incubated in frozen ethanol (2 min) and 4% paraformaldehyde (4 minutes). After 3 washes in phosphate-buffered saline (PBS) containing Tween 20 (PBS/T) (Sigma-Aldrich, Rehovot, Israel), the sections were incubated for 60 minutes in a blocking solution and then incubated overnight at 4 °C with primary antibodies against NPY(1-36) (rabbit monoclonal anti-NPY antiserum (1:100), product code: ab-221145, Abcam) and NPY-Y1R (rabbit polyclonal anti-NPY-Y1 antiserum (1:500), product code: NBP1-59008, Novus Biologicals). After 3 washes in PBS/T, sections were incubated in DyLight-594 labeled goat-anti-rabbit IgG (1:1000; Thermo Fisher Scientific Inc., Waltham, Massachusetts) in PBS containing 2% normal goat or mouse serum for 2 hours. Sections were washed and mounted with mounting medium (Vectastain Vector laboratories, California, USA). Control staining was performed in the absence of the primary antibodies. Control staining was performed in the absence of the primary antibodies. Quantification: Brain sections exhibiting NPY immunoreactivity (NPY-ir) in the PVN, PVTN, CA1, and amygdala were analyzed. Each brain region was identified under the microscope based on cytoarchitectural landmarks (Paxinos and Watson, 2013). NPY-ir cells and fibers were quantified within a 50 000 µm² area, using digitized microscopic images captured with a Leica DM4500B microscope and a DFC340FX digital camera (Leica Microsystems, Wetzlar, Germany). Measurements were taken from predetermined fields in each subregion from both hemispheres. The density of NPY-ir fibers and cells in each area was calculated using Leica LAS software (version 3.8). Fluorescent labeling for all specimens was performed on the same day, and image acquisition was conducted under identical settings, including exposure time, gain, and gamma. Background fluorescence was subtracted to normalize signal intensity, and inter-rater reliability was ensured by having multiple observers analyze the data. All analyses were carried out by observers blinded to the experimental conditions. ELISA Assay of NPY Tissue preparation: Animals were decapitated with a guillotine in a separate room from the one used for behavioral tests, 24 hours after the last behavioral tests (between 14:00 and 15:00). Brains were removed, and the amygdala (AMY), hippocampus (HIP), and hypothalamus were dissected on ice and frozen at −80° C until used. Each sample was coded, and analyses were performed blind to groups. ELISA assay: The brain tissues were homogenized, ultrasonicated, and twice extracted in 1 M acetic acid and water. After centrifugation, the supernatants were lyophilized and stored at −28 °C until further analysis. The lyophilized samples were reconstituted and diluted in phosphate buffer before analysis by ELISA. NPY(1-36) concentrations were determined using ELISA kits (ENCO Scientific Services, Israel), according to the manufacturer’s instructions, by a technician blind to the drug treatment condition. All samples were measured in duplicate. Statistical Analysis Behavioral and immunohistochemical data were analyzed using one-way analysis of variance in which PSS exposure was the independent factor (sham-PSS vs PSS). Where significant group effects were detected, the Bonferroni test assessed significant post hoc differences between groups. The prevalence of affected rats was tested based on the rat group using cross-tabulation and nonparametric Fisher exact tests. RESULTS Experiment 1 Anxiety-Like Response in EPM at Day 7 Post-PSS Exposure In terms of the anxiety index (Figure 1F), a significant effect was observed between groups (F(4,48) = 3.3, P < .02). The Bonferroni test confirmed a significant increase in the overall anxiety index for the exposed groups treated with vehicle or DPP-IV-I at doses of 10 mg/kg and 20 mg/kg for 3 days (P < .045, P < .05, and P < .04, respectively) compared to the unexposed controls. Please see Supplementary Information 2 for all EPM parameters. Anxiety-like response in EPM at day 7 post-PSS exposure. (1) Top panel: experimental protocol: rats were exposed to predator scent stress (PSS) or sham-PSS for 30 minutes. Sixty minutes later, they were injected with DPP-IV-I at doses of 10 mg/kg (N = 10), 30 mg/kg (N = 10), or saline (N = 12). Another group of rats received sitagliptin at a dose of 20 mg/kg (N = 9), beginning 1 hour after PSS exposure and continuing for 3 consecutive days. Seven days post-exposure, the rats were tested using the elevated plus maze (EPM) and acoustic startle response (ASR). (A) Overall Anxiety Index, which integrates the behavioral measures of the EPM. (B) Startle amplitude in the ASR paradigm; (C) startle duration (ms); (D) representative accumulated movement track during a trial. The closed arms of the maze are shown in yellow, and the open arms in white. (E) Prevalence of extreme post-stress behavioral responses (EBRs; in percentage); (F) prevalence of minimal post-stress behavioral responses (MBRs; in percentage); (G) prevalence of partial post-stress behavioral responses (PBRs; in percentage). ASR, acoustic startle response; DPP4-I, dipeptidyl peptidase-IV inhibitor; EPM, elevated plus maze; PSS, predator scent stress. Bars represent group mean ± S.E.M (A–C) or percentage (E–G). Hyperarousal in ASR at Day 7 Post-PSS Exposure In terms of the mean startle amplitude (Figure 1B), a significant effect was observed between groups (F(4,48) = 13.8, P < .0001). The Bonferroni test confirmed a significant increase in the mean startle amplitude for the exposed groups treated with vehicle or DPP-IV-I at all doses (10 mg/kg, 30 mg/kg, and 20 mg/kg for 3 days) (P < .0001, P < .0001, P < .0001, and P < .0008, respectively) compared to the unexposed controls. Regarding the mean startle duration (Figure 1C), a significant effect was observed between groups (F(4,48) = 5.7, P < .0008). The Bonferroni test confirmed a significant increase in the mean startle amplitude for the exposed groups treated with vehicle or DPP-IV-I at doses of 10 mg/kg and 30 mg/kg (P < .008, P < .0001, and P < .05, respectively) compared to the unexposed controls. In summary, there were no significant differences observed between the treated and control exposed rats regarding mean startle amplitude and mean startle duration on day 7. Relative Prevalence Rates According to Cutoff Behavioral Criteria According to Figure 1E, the prevalence of extreme behavioral responses (EBRs) animals among PSS-exposed, saline-treated rats was 25% of the total population (3/12). While the difference was not statistically significant, there was a noticeable trend close to significance when compared to the unexposed/vehicle non-EBR individuals (χ2 = 3.43, P = .064). The prevalence of EBR among exposed animals treated with DPP-IV-I at doses of 10 mg/kg and 30 mg/kg was 30% for both groups (3/10), indicating a significant difference from the respective parallel unexposed groups (χ2 = 4.17, P < .045). Additionally, the prevalence of EBR animals among exposed animals treated with DPP-IV-I at a dose of 20 mg/kg for 3 days was 22.22% of the total population (2/9). While the difference was not statistically significant, there was a noticeable trend close to significance when compared to the unexposed/vehicle non-EBR individuals (χ2 = 2.95, P = .086). Significant differences were observed among the groups in the prevalence rates of animals exhibiting MBRs (Pearson χ2 = 11.7, df = 4, P < .02). As illustrated in Figure 1F, the prevalence of MBR animals among unexposed rats treated with saline was 41.67% of the total population (5/12), which significantly differed from the exposed groups treated with DPP-IV-I at doses of 10 mg/kg and 20 mg/kg for 3 days, both of which showed no MBR individuals (χ2 = 5.39, P < .02 and χ2 = 4.92, P < .03, respectively). Additionally, the prevalence of MBR animals among exposed animals treated with saline or DPP-IV-I at a dose of 30 mg/kg was 8.33% (1/12) and 10% (1/10), respectively. While the difference was not statistically significant, there was a noticeable trend close to significance when compared to the unexposed/vehicle individuals (χ2 = 3.56, P = .059 and χ2 = 2.76, P = .096, respectively). As depicted in Figure 1G, the prevalence of partial behavioral responses animals among exposed animals treated with saline or DPP-IV-I at doses of 10 mg/kg, 30 mg/kg, and 20 mg/kg for 3 days was 58.33% (7/12), 66.67% (8/12), 70% (7/10), 60% (6/10), and 77.78% (7/9), respectively. Experiment 2 To evaluate the impact of DPP-IV-I administration on brain NPY levels, we sacrificed rats exposed to either PSS or sham-PSS, 2 hours after administering sitagliptin at a dosage of 30 mg/kg or saline and collected their brains for immunohistochemical staining. Using a computer-assisted imaging system, we quantitatively analyzed the density of immunoreactive (ir) NPY and NPY-Y1R fibers and/or cells in various hypothalamic, hippocampal areas, and amygdala. NPY-ir In the PVN (Figure 2A), PVTN (Figure 2B), hippocampal CA1 (Figure 2C), and amygdala (Figure 2D) subregions, significant effects were observed between groups (F(2,5) = 12.8, P < .0015, F(2,4) = 14.5, P < .0085, F(2,5) = 18.8, P < .005, and F(2,6) = 14.7, P < .005, respectively). Bonferroni tests revealed that rats exposed to PSS and treated with saline exhibited a significantly lower density of NPY-ir cells and fibers compared with rats exposed to sham-PSS, in the PVN (P < .035), CA1 subregion (P < .006), and amygdala (P < .0075). Rats exposed to PSS and treated with DPP-IV-I exhibited a significantly higher density of NPY-ir cells and/or fibers in the PVN (P < .015), PVTN (P < .01), CA1 (P < .03), and amygdala (P < .02) compared to those treated with saline. These findings suggest that DPP-IV-I is involved, at least in part, in upregulating the densities of NPY protein following PSS exposure. DPP-IV-I injection increases the immunoreactivity of NPY in the hypothalamic, hippocampal, and amygdala areas. (1) Top panel: experimental protocol: rats were exposed to predator scent stress (PSS) or sham-PSS for 30 minutes and then injected with DPP-IV-I (30 mg/kg) or saline 60 minutes later. After 2 hours, the rats were sacrificed, and their brains were removed for immunoreactivity analysis. Quantitative morphometric analysis of NPY immunoreactivity was conducted in cells of the PVN (A), PVTN (B), CA1 (C), and amygdala (D). (E) Schematic drawing illustrating the areas analyzed in coronal sections of the rat brain at Bregma −1.8 mm using quantitative receptor autoradiography. (F) Schematic drawing illustrating the areas analyzed in coronal sections of the rat brain at Bregma −2.8 mm using quantitative receptor autoradiography. (G) Representative images of NPY immunoreactivity in the hypothalamic, hippocampal, and amygdala areas were captured for all groups. ; ASR, acoustic startle response; CA1, cornu ammonis 1; DPP4-I, dipeptidyl peptidase-IV inhibitor; EPM, elevated plus maze; PSS, predator scent stress; PVN, paraventricular nucleus of the hypothalamus; PVTN, paraventricular thalamic nucleus. All data represent group mean ± S.E.M. NPY-Y1-ir In the PVN (Figure 3A), PVTN (Figure 3B), hippocampal CA1 (Figure 3C), and amygdala (Figure 3D) subregions, significant effects were observed between groups (F(2,6) = 9.5, P < .015, F(2,6) = 14.0, P < .006, F(2,6) = 17.8, P < .003, and F(2,6) = 20.2, P < .0025, respectively). Bonferroni post hoc tests revealed that rats exposed to PSS and treated with either saline or DPP-IV-I exhibited a significantly lower density of NPY-Y1-ir cells and fibers compared with rats exposed to sham-PSS, in the PVN (P < .02 and P < .05, respectively), PVTN (P < .015 for both groups), CA1 subregion (P < .0075 and P < .0055, respectively), and amygdala (P < .015 and P < .0025, respectively). In summary, no significant differences were observed between PSS-exposed rats treated with DPP-IV-I and saline regarding the presence of NPY-Y1 positive cells in the PVN, PVTN, CA1, and amygdala regions. These results confirm that despite the notable increase in NPY levels in these brain areas, the activation of the NPY-Y1 system within these subregions is necessary for the behavioral anxiolytic response to DPP-IV-I after PSS exposure. DPP-IV-I injection did not alter NPY-Y1 immunoreactivity levels in the hypothalamic, hippocampal, and amygdala areas. (1) Top panel: experimental protocol: rats were exposed to predator scent stress (PSS) or sham-PSS for 30 minutes and then injected with DPP-IV-I (30 mg/kg) or saline 60 minutes later. After 2 hours, the rats were sacrificed, and their brains were removed for immunoreactivity analysis. Quantitative morphometric analysis of NPY-Y1 immunoreactivity was conducted in cells of the PVN (A), PVTN (B), CA1 (C), and amygdala (D). (E) Schematic drawing illustrating the areas analyzed in coronal sections of the rat brain at Bregma −1.8 mm using quantitative receptor autoradiography. (F) Schematic drawing illustrating the areas analyzed in coronal sections of the rat brain at Bregma −2.8 mm using quantitative receptor autoradiography. (G) Representative images of NPY-Y1 immunoreactivity in the hypothalamic, hippocampal, and amygdala areas were captured for all groups. ASR, acoustic startle response; CA1, cornu ammonis 1; DPP4-I, dipeptidyl peptidase-IV inhibitor; EPM, elevated plus maze; PSS, predator scent stress; PVN, paraventricular nucleus of the hypothalamus; PVTN, paraventricular thalamic nucleus. All data represent group mean ± S.E.M. ELISA NPY Concentration As shown in Table 1, there were significant group differences in NPY concentrations across the hippocampus, amygdala, and hypothalamus (F(2,7) = 8.5, P < .015; F(2,7) = 21.9, P < .001; and F(2,7) = 9.7, P < .01, respectively). Bonferroni post hoc tests revealed that rats exposed to PSS and treated with saline exhibited significantly lower NPY concentrations compared to sham-PSS rats in the hippocampus (P < .02), amygdala (P < .003), and hypothalamus (P < .025). Additionally, rats exposed to PSS and treated with DPP-IV-I had significantly higher NPY concentrations in the amygdala (P < .0015) and hypothalamus (P < .02) compared to those treated with saline. In the hippocampus, rats exposed to PSS and treated with DPP-IV-I showed higher NPY concentrations than those treated with saline, though the difference was not statistically significant (P = .06). These findings suggest that DPP-IV-I may play a role in upregulating NPY levels following PSS exposure. Table 1.DPP-IV-I Injection Increases NPY1-36 Protein Levels in the Hypothalamic, Amygdala and Hippocampal Areas.UnexposedSalineN = 3IPSS + SalineN = 3IIPSS + DPP4-I 30 mg/kgN = 4IIIHippocampus (pg/mg)a513.3 ± 23.1402.67 ± 12.35519.5 ± 4.7I ≠ IIAmygdala (ng/mL)b728.0 ± 63.9570.1 ± 26.35694.5 ± 30.26II ≠ I, IIIHypothalamus (ng/mL)c404.0 ± 36.52268.7 ± 21.73399.75 ± 14.6II ≠ I, IIIAll data represent group mean ± S.E.M. a F(2,7) = 8.5, P < .015. b F(2,7) = 21.9, P = .001. c F(2,7) = 9.7, P = .01.Abbreviations: DPP-IV-I, dipeptidyl peptidase-IV inhibitor; NPY, neuropeptide Y; PSS, predator scent stress. DPP-IV-I Injection Increases NPY1-36 Protein Levels in the Hypothalamic, Amygdala and Hippocampal Areas. All data represent group mean ± S.E.M. a F(2,7) = 8.5, P < .015. b F(2,7) = 21.9, P = .001. c F(2,7) = 9.7, P = .01. Abbreviations: DPP-IV-I, dipeptidyl peptidase-IV inhibitor; NPY, neuropeptide Y; PSS, predator scent stress. DISCUSSION In this study, a prospective animal model for PTSD demonstrated that immediate post-exposure with DPP-IV-I sitagliptin was ineffective in preventing PTSD-like behavioral responses. We conducted 2 complementary experiments to investigate the behavioral and molecular effects of early DPP-IV-I administration following PSS. We did not observe the expected reduction in anxiety-like behavior in rats treated with DPP-IV-I compared to the saline group. Furthermore, no significant effect on the prevalence rates of individuals exhibiting EBR patterns was observed for either dose of DPP-IV-I compared to the vehicle. The immediate post-stressor administration of DPP-IV-I was ineffective in attenuating stress-induced behavioral disruption. The likelihood of treated individuals developing EBRs resembling PTSD was indistinguishable from that of the exposed controls. The same treatment regimen of 30 mg/kg (using the same batch of DPP-IV-I at the same dose), which had previously been ineffective in attenuating stress-induced behavioral disruption, significantly increased NPY levels as measured by 2 different methods: immunohistochemistry and ELISA. Immunohistochemistry revealed that DPP-IV-I treatment significantly elevated NPY levels in the PVN, PVTN, amygdala, and the CA1 region of the hippocampus. Similarly, ELISA demonstrated a significant increase in NPY levels in both the hypothalamus and amygdala. In the hippocampus, we observed only a trend toward increased NPY levels, likely because the entire hippocampal region was analyzed rather than focusing specifically on the CA1 region, as done with immunohistochemistry. The observed increase in NPY levels in rats treated with 30 mg/kg DPP-IV-I compared to those given saline may be attributed to the inhibition of dipeptidyl peptidase-IV, which increases the bioavailability of NPY1-36. Consequently, this elevated prevalence may enhance its binding to the NPY-Y1 receptor at the expanse of Y2 and Y5 (Fuhlendorff et al., 1990; King et al., 2000). These findings contradict reports of the beneficial behavioral effects observed in animal studies following the administration of exogenous acute NPY. It is suggested that NPY might act as a resilience factor, attenuating fear-associated memories as a regulatory mechanism to mitigate inappropriate or exaggerated fear responses following stress exposure, as proposed previously (Sajdyk et al., 2008; Cohen et al., 2012; Serova et al., 2013, 2014; Laukova et al., 2014). However, the outcomes of models involving chronic NPY overexpression have been inconsistent. A transgenic rat model that overexpressed NPY showed no alteration in baseline anxiety behavior (Thorsell et al., 2000) or in fear learning and extinction (Corder et al., 2020), whereas viral-mediated NPY overexpression in the hippocampus induced a mild anxiolytic effect (Lin et al., 2010). However, the discrepancy between the acute anxiolytic effects of exogenous NPY brain infusions and the lack of behavioral response to NPY upregulation via sitagliptin treatment may be attributed to the availability of NPY for release. The increase in intracellular NPY following sitagliptin treatment does not necessarily imply that NPY is being released into the extracellular space where it can interact with its receptors. Instead, NPY may remain stored in dense core vesicles and may not be readily secreted under baseline or stress conditions unless triggered by specific stimuli, such as neuronal activation. In contrast, exogenously administered NPY is immediately released into the extracellular space, where it has direct access to postsynaptic receptors, leading to observable behavioral effects. Contrary to the significant increase in NPY levels observed in these brain areas, DPP-IV-I did not influence the expression of NPY-Y1-ir levels. No notable differences were observed in the NPY-Y1 levels among PSS-exposed rats treated with either DPP-IV-I or saline in the PVN, PVTN, amygdala, and CA1 regions. The diverse effects of NPY overexpression on behavior may be contingent upon several factors, including the specific receptor subtype, brain region, and neural pathway involved. This consideration is particularly crucial given the association of different NPY receptors with distinct behavioral responses. Typically, NPY overexpression in the brain may not selectively target a specific receptor; it could potentially influence various receptors, such as NPY-Y2, which is recognized for its region-specific anxiogenic effects. In this study, despite NPY1-36 recognized as a potent Y1R agonist while NPY3–36 remains inactive at Y1Rs (Michel et al., 1998; Berglund et al., 2003), the use of a DPP-IV-I was expected to modify the biological effects of endogenous NPY1-36, thereby enhancing Y1R activation. However, we did not observe a change in the expression of Y1Rs. Additionally, there is evidence suggesting that the overexpression of NPY ligand could induce desensitization of its receptors, a phenomenon frequently observed in G protein-coupled receptors when there is an abundance of ligands (Gainetdinov et al., 2004). Receptor desensitization may stem from diminished receptor surface expression within the neuron (Böhm et al., 1997), and/or a reduction in the efficiency of receptor signaling (Gainetdinov et al., 2004). Kempf et al. (2015) investigated the internalization pathway of the NPY-Y1-activated complex. Their findings confirmed that these complexes undergo rapid internalization via endocytosis, leading to swift desensitization of Y1 receptors upon exposure to agonists. Our previous work confirmed the anxiolytic effect of NPY microinjected 1 hour after PSS, which was accompanied by a significant upregulation of both NPY and NPY-Y1 receptors compared with exposed animals treated with vehicle (Cohen et al., 2012). Moreover, previously, we reported that a single dose of NPS microinfused bilaterally into the basolateral amygdala (BLA) 1 hour after PSS exposure resulted in a significant moderation of behavioral patterns representing stress-induced anxiety, avoidance, and hyperarousal responses in the EPM and ASR tests (Cohen et al., 2018). This anxiolytic-like effect of neuropeptide S (NPS) was accompanied by significant upregulation of hippocampal NPY-Y1R-ir levels compared to rats that received Artificial cerebrospinal fluid (ACSF) treatment. In contrast, NPS did not affect the expression of NPY-ir levels (Cohen et al., 2018). In line with our current findings, which demonstrate that elevated endogenous NPY levels as a result of DPP-IV-Inhibition do not affect behavioral stress responses, it may be inferred that receptors play a more crucial role than the peptide itself. In other words, selective agonism of NPY-Y1 receptors or antagonism of NPY-Y2 receptors could potentially serve as valuable components in anti-anxiety or stress-related therapeutics. Interestingly, Bacchi et al (2006) reported that both NPY and the selective NPY-Y2 antagonist (BIIE0246) have an anxiolytic-like effect in the elevated plus maze test in rats. Similar behavioral results have been reported with omarigliptin, a DPP-IV inhibitor that can cross the BBB either after oral administration or via the intranasal route (Ayoub et al., 2018; Nahvi et al., 2021). The authors reported that intranasal administration of omarigliptin (1200 μg), either alone or in combination with NPY (600 μg), when given immediately after stress, did not significantly prevent the development of stress-induced anxiety-like behavior in female rats (Nahvi et al., 2019). In contrast to anxiety-related behavior, the combined treatment, omarigliptin and NPY (600 µg), but neither alone, was sufficient at preventing depressive-like behavior on the swim test. The authors suggested that the administration of omarigliptin at high NPY levels may shift the actions of NPY from Y2/Y5 to Y1 receptors, and the anti-depressive effects of intranasal NPY in females can be attributed to its action on Y1R (Nahvi et al., 2019). If this were the case, we would expect an anxiolytic response in the EPM; however, such a result was not obtained in Nahvi et al. (2019). Similarly, in our findings, the administration of DPP-IV-I, even in the presence of high NPY levels, did not reduce anxiety levels. Similarly, in our findings, the administration of DPP-IV-I, even in the presence of high NPY levels, did not reduce anxiety levels. Importantly, DPP-IV inhibitors could affect several anxiety-relevant peptides beyond NPY, including substance P (SP), GLP-1, peptide YY, and endorphins, all of which modulate stress and anxiety responses (Shao et al., 2020). Most DPP-IV inhibitors, including sitagliptin, do not cross the BBB (Darsalia et al., 2013, 2014; Lin and Huang, 2016; Mousa and Ayoub, 2019). Consequently, their therapeutic effects are likely attributable to peripheral mechanisms, including the systemic improvement of glucose homeostasis and insulin signaling pathways (or NPY levels) and/or by the activation of the neutrally mediated gut-to-brain-to-periphery axis (Waget et al., 2011). Recent studies indicate that DPP-IV-I may possess neuroprotective properties in various experimental models of brain disease (Nassar et al., 2015; Badawi et al., 2017; Kosaraju et al., 2017). These inhibitors increase the levels of GLP-1 in the circulation, which crosses the BBB (Kastin et al., 2002), binds to the GLP-1 receptor, and mitigates neurodegeneration and neuronal resistance (Siddiqui et al., 2023). However, under conditions of a disrupted BBB, such as during stress (Sántha et al., 2015; Welcome and Mastorakis, 2020), DPP-IV inhibitors may penetrate the brain directly (Srinivas, 2015). They might also access the brain via circumventricular organs or bind to DPP-IV on the luminal membrane of brain endothelial cells, inhibiting its activity (Bernstein et al., 2023). Thus, NPY signaling, its proteolytic processing, the regulation of various physiological functions, and its involvement in stress-related disorders encompass various mechanisms. These include interactions with multiple receptor subtypes, modulation of the hypothalamic-pituitary-adrenal axis, and participation in both central and peripheral stress response pathways, leading to an integrated response within a complex and multifaceted network. Despite the wealth of compelling evidence from both animal and human studies, there remains a notable absence of developed therapeutic strategies aimed at enhancing NPY signaling for the treatment of PTSD or other stress-related disorders. The future exploration of selective nonpeptide NPY-Y1 receptor agonists holds promise for the development of novel pharmaceuticals targeting anxiety, PTSD, and other stress-related disorders. CONCLUSION Our study sheds light on the complexity of NPY signaling in stress-related disorders. While previous research suggests that exogenous NPY administration as secondary prevention may have beneficial effects, our findings indicate that acutely increased endogenous NPY levels, induced by DPP-IV inhibition early after PSS, did not produce the expected behavioral outcomes when evaluated 7 days post-treatment. This suggests that the role of NPY in stress regulation may be more nuanced than previously thought. Furthermore, our results highlight the importance of considering receptor dynamics in NPY signaling. Despite an increase in NPY levels, we observed no changes in NPY-Y1 receptor expression, implying that the effectiveness of NPY signaling may depend on factors beyond peptide concentration alone. Our study underscores the need for further research to elucidate the complexities of NPY signaling in stress-related disorders. Despite the challenges encountered, exploring selective nonpeptide NPY-Y1 receptor agonists remains a promising strategy for developing novel therapeutics for anxiety, PTSD, and other stress-related disorders. Supplementary Material